What a Peptide or GLP-1 Clinic Can and Cannot Say in Ads

Quick answer

A peptide or GLP-1 clinic can make only the health claims it can substantiate with competent and reliable scientific evidence, which FTC staff guidance says generally means randomized, controlled human clinical trials (FTC Health Products Compliance Guidance). For compounded drugs, FDA says promotion may not call them generic versions of, the same as, or the same active ingredient as an FDA-approved drug, or "clinically proven" (FDA, February 6, 2026). Images and testimonials create claims just as text does, and words such as "may" or "helps" do not fix a claim the evidence does not support.

This article is for prescriber-led clinics, telehealth operators, med spas and the people who write their ads. It covers what FTC and FDA have said about health claims, compounded drugs and endorsements. It is part of our peptide advertising compliance guide.

Which laws govern what a clinic says in ads?

Two federal agencies reach clinic advertising.

The FTC Act. Section 5 prohibits "unfair or deceptive acts or practices in or affecting commerce" (15 U.S.C. § 45). Section 12 makes it unlawful to disseminate a false advertisement for food, drugs, devices, services or cosmetics (15 U.S.C. § 52). A "false advertisement" is one that is "misleading in a material respect," and the statute counts representations "made or suggested by statement, word, design, device, sound, or any combination thereof" (15 U.S.C. § 55).
The FD&C Act. A compounded drug is misbranded "if the advertising or promotion of a compounded drug is false or misleading in any particular" (21 U.S.C. § 352(bb)).

Only the statutes and FTC orders bind. The Health Products Compliance Guidance and .com Disclosures are FTC staff guidance, and the Endorsement Guides are "administrative interpretations" (16 C.F.R. § 255.0(a)). They show how the FTC reads the law.

What evidence does a health claim need?

FTC staff guidance says health claims require "competent and reliable scientific evidence," defined as tests, analyses, research or studies "conducted and evaluated in an objective manner by experts" and "generally accepted in the profession to yield accurate and reliable results" (HPCG, p.11). What that means in practice, per the same guidance:

Type of evidence	What FTC staff guidance says
Randomized, controlled human trials	"As a general matter," health benefit claims need RCTs. There is "no requirement for a specific number of RCTs," but independent replication adds weight (p.11 to 12).
Epidemiologic studies	Accepted only in limited cases, where experts treat them as an acceptable substitute and RCTs are not feasible (p.13).
Animal and in vitro studies	Useful background, but "without confirmation by human RCTs, they aren't sufficient to substantiate health-related claims" (p.13).
Testimonials, anecdotes, customer surveys	"Never sufficient to substantiate claims about the effects of a health product" (p.13).

Relevance matters too. The guidance says advertisers should ask how the formulation of the advertised product compares to the product studied (p.17).

In 2023 the FTC sent Notices of Penalty Offenses on substantiation to about 670 marketers of OTC drugs, homeopathic products, supplements and functional foods (FTC, April 13, 2023). The notice lists claiming "scientifically or clinically proven" without adequate evidence as unlawful (Notice). A company that knowingly does what it describes can face civil penalties, currently up to $53,088 per violation (16 C.F.R. § 1.98).

Why don't words like "may" or "helps" fix a claim?

Because readers do not hear them as limits. FTC staff guidance says: "Vague qualifying terms are inadequate. For example, it's not enough to say that the product 'may' have the claimed benefit or 'helps' achieve the claimed benefit" (HPCG, p.8). Consumers are also likely to read "promising" or "preliminary" as positive attributes rather than as limits on the science.

A disclosure also "can't directly contradict a claim" (p.9). In the guidance's example, an "entertainment purposes only" disclaimer does not cancel an express treatment claim.

What counts as an implied claim?

Anything the ad suggests as a whole. "Marketers can't suggest benefits, safety, or other characteristics about their product indirectly that they couldn't claim directly," and each ad is judged on its "net impression," including "the text, product name, and any charts, graphs, and other images" (HPCG, p.4 to 6). Two examples from the guidance matter for clinics:

Images of doctors in white lab coats looking through microscopes "likely convey an implied claim that the product has been clinically proven to be effective for weight loss" (Example 1).
Before-and-after images, combined with references to a condition, can convey a claim of dramatic improvement (Example 6). "Results not typical" statements "don't cure the deception" (p.26).

Platform rules add a second layer, and they change often. As of October 2026, Meta's weight-loss policy no longer contains its former ban on before-and-after images. The version with the change log entry dated July 22, 2026 allows dietary weight-loss ads targeted to adults to show people using the product and its impact, with the time taken to see results, and still bars close-ups of pinched fat and statements of inferiority about appearance (Meta Health and Wellness policy). Weight-loss products that require a prescription fall under Meta's Drugs and Pharmaceuticals policy instead. Meta also does not allow ads that assert or imply a viewer's health condition, such as "Do you have diabetes?" (Meta personal attributes policy). TikTok restricts weight-management claims to adults and bars unrealistic or guaranteed results (TikTok). A platform allowing an image does not substantiate the claim it makes. See Google, Meta and TikTok ad rules for peptide and GLP-1 clinics for the full platform picture.

What are the rules for testimonials and endorsements?

The FTC's Endorsement Guides (16 C.F.R. Part 255, revised 2023) set out how the FTC reads endorsements:

Testimonials are not evidence. "Consumer endorsements themselves are not competent and reliable scientific evidence" (§ 255.2(a)).
Testimonials imply typical results. A patient story about a key result will likely be read as what consumers will generally achieve. Without substantiation that it is representative, the ad "should clearly and conspicuously disclose the generally expected performance" (§ 255.2(b)).
Endorsers must be real users. "The endorser must have been a bona fide user of it at the time the endorsement was given" (§ 255.1(c)).
Connections must be disclosed. Payment, free or discounted products, and business, family or personal relationships are material connections that must be disclosed clearly and conspicuously (§ 255.5(a)).
The clinic answers for its endorsers. "Advertisers are subject to liability for misleading or unsubstantiated statements made through endorsements" (§ 255.1(d)).
Disclosures must be unavoidable online. A disclosure only on a profile page, or behind a "more" link, is not clear and conspicuous (§ 255.0(g), Example 9).

Disclosures should match the medium: on screen for a visual claim, spoken for a spoken one, both for both (§ 255.0(f)). FTC staff guidance says to place them "as close as possible to the triggering claim," and not to put health and safety disclosures integral to a claim behind a hyperlink (.com Disclosures). No FTC rule sets a numeric contrast ratio.

This has reached GLP-1 telehealth directly. In July 2025 the FTC charged a GLP-1 telehealth firm over ads with undisclosed drug and lab costs, unsupported average weight-loss figures, fake reviews, and testimonials and before-and-after photos from non-customers. The final order in December 2025 required $150,000 for consumer refunds (FTC, July 14, 2025; FTC, December 3, 2025).

What can a clinic say about compounded GLP-1s?

Start from FDA's own sentence: "Compounded drugs are not approved by FDA" (FDA). The shortage-based allowance to compound copies has ended. FDA's final decision that the tirzepatide shortage was resolved came on December 19, 2024, the semaglutide shortage was declared resolved on February 21, 2025, and the compounding grace periods ended in 2025, the last on May 22, 2025.

On February 6, 2026 FDA stated: "In promotional materials, companies cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA. They also cannot state compounded drugs use the same active ingredient as the FDA-approved drugs or that compounded drugs are clinically proven to produce results for the patient" (FDA).

Phrase in promotion of a compounded drug	What FDA has said
"Generic version of" an approved drug	FDA says not allowed (FDA statement, February 6, 2026).
"Same as" an approved drug	FDA says not allowed (same statement). Implied sameness was a primary violation in the 30 telehealth letters announced March 3, 2026.
"Same active ingredient as" an approved drug	FDA says not allowed (same statement).
"Clinically proven"	FDA says not allowed (same statement). FDA's September 9, 2025 letter to Slendid found "clinically proven weight loss treatments" misleading.
The clinic's own brand name on the drug, without qualification	Cited in the March 3, 2026 letters as "obscuring product sourcing," implying the telehealth firm is the compounder.

The enforcement record behind those lines:

On September 9, 2025 FDA announced it was sending "thousands of letters" and "approximately 100 cease-and-desist letters to companies with deceptive ads" (FDA).
Slendid received an FDA warning letter dated September 9, 2025 citing "clinically proven weight loss treatments" for compounded semaglutide and tirzepatide. FDA wrote: "Your claim implies that your products are the same as an FDA-approved product when they are not," and found the products misbranded under sections 502(a) and 502(bb) (FDA warning letter).
GLP-1 Solution received an FDA warning letter dated September 9, 2025 citing semaglutide and tirzepatide claims as misleading under sections 502(a) and (bb) (FDA warning letter).
On March 3, 2026 FDA announced warning letters to 30 telehealth companies, citing sameness claims and drugs branded with the telehealth firm's name "without qualification, implying they are the compounder" (FDA).

Can an ad name a brand-name drug or compare to one?

The problem FDA's letters and statements identify is implying that a product is, or equals, an approved drug. Two letters show how FDA reads names and comparisons:

Prime Sciences received an FDA warning letter dated March 31, 2026 that quotes its copy "Ozempic – Weight Loss Supplement" and decodes its product "GLP1-S" as semaglutide (FDA warning letter).
Royal Peptides LLC received an FDA warning letter dated August 24, 2026 that treats blog comparison posts such as "Tirzepatide vs Retatrutide" as labeling (FDA warning letter). A comparison article on a site that sells the product is part of how FDA reads that product.

For a compounded drug, any comparison that suggests sameness with the approved product runs into the FDA statement above. Platforms have their own rules on drug names. As of October 2026, semaglutide, liraglutide and tirzepatide are on Google's prescription drug terms list (Google). In the US, those terms may appear in ads and on landing pages without certification, but keyword-targeting them requires Google certification (Google restricted drug terms).

Research-chemical sellers face a separate problem: the product itself is unapproved. That is covered in why "Research Use Only" does not protect a peptide business.

How should a clinic review a claim before it runs?

This is the method we recommend. It is a working process, not a legal standard.

List every claim, express and implied, including what the images, product names and testimonials suggest.
Match each claim to evidence: human RCTs on a relevant product for a health benefit. Animal studies, cell studies and patient stories do not count on their own.
Cut qualifiers that do the work. If a claim only survives with "may" in front of it, narrow it to what the evidence supports or remove it.
Run the compounded-drug check: no "generic," "same as," "same active ingredient" or "clinically proven," and no branding that implies the clinic is the compounder.
Check every testimonial for a real patient, any material connection, and a typical-results disclosure where needed.
Place disclosures where the claim is, in the same medium.
Review the destination. Google and Meta both say their review can include the landing page or website (Google; Meta).
File the evidence for each ad, dated, so the clinic can show what it relied on.

Legal disclaimer: This article is for informational purposes only and is not legal, regulatory or compliance advice. FTC and FDA enforcement and platform policies change. Consult qualified legal counsel before running health claims in any advertising. Information reflects primary sources checked on October 4, 2026.

Prescriber-Led Peptide Programs, Built In

LUKE gives clinics prescription-gated checkout: a product the clinic flags as requiring a prescription cannot be purchased without an active, verified prescription, enforced at checkout and in the database. Advertising and marketing services are provided by Ernesto Cullari Media LLC, LUKE's agency partner, under a separate agreement. They are not part of a LUKE software subscription. Read about advertising services.

Request a Demo Read the peptide advertising compliance guide →

Frequently asked questions

Can a clinic say compounded semaglutide is the same as Ozempic?

No. FDA stated on February 6, 2026 that promotional materials cannot claim non-FDA-approved compounded products are generic versions of or the same as FDA-approved drugs, or that they use the same active ingredient. Claims implying sameness were a primary violation in the 30 telehealth warning letters FDA announced on March 3, 2026.

Can a clinic call a compounded GLP-1 program "clinically proven"?

No. FDA's February 6, 2026 statement says companies cannot state that compounded drugs are clinically proven to produce results for the patient. FDA's September 9, 2025 warning letter to Slendid found the phrase "clinically proven weight loss treatments" misleading for compounded semaglutide and tirzepatide.

Does adding "may help" make a health claim safe?

No. FTC staff guidance says vague qualifiers are inadequate and that it is not enough to say a product "may" have a benefit or "helps" achieve it. It also says consumers tend to read words like "promising" or "preliminary" as positive attributes rather than as limits on the science.

Does every health claim need a randomized controlled trial?

FTC staff guidance says health benefit claims generally need randomized, controlled human clinical trials, with no fixed number required. Epidemiologic evidence is accepted only in limited cases, and animal or in vitro studies are not sufficient without confirmation by human trials. Testimonials never substantiate a health claim.

Can a clinic use patient testimonials in ads?

Yes, with limits. Under the FTC's Endorsement Guides, testimonials are not scientific evidence, a testimonial about a key result implies typical results unless the ad discloses the generally expected performance, endorsers must be real users, and paid or gifted connections must be disclosed clearly and conspicuously. The clinic can be liable for what its endorsers say.

Does Meta still ban before-and-after photos in weight-loss ads?

Not as a blanket rule, as of October 2026. Meta's Health and Wellness policy, as of the change log entry dated July 22, 2026, allows dietary weight-loss ads targeted to adults to show the product's impact and the time taken, while barring close-ups of pinched fat and statements of inferiority about appearance. Prescription weight-loss products fall under Meta's Drugs and Pharmaceuticals policy, and FTC rules on implied claims still apply.